Immuron Sees Revenue Surge Amid Higher R&D Costs

Immuron (IMRN) has released an update.

Immuron Limited reported a significant increase in revenue, up 171.7% to $4.9 million for the year ended June 30, 2024, primarily driven by a strong sales recovery in the Australian, U.S., and North American markets for their Travelan product. Despite this, the company incurred a higher net loss of $6.9 million, up 83.2% from the previous year, largely due to substantial research and development expenses. No dividends were paid or declared for the year, and the company’s cash position remains solid at $11.7 million.

For further insights into IMRN stock, check out TipRanks’ Stock Analysis page.